 |
市场调查报告书
商品编码
1190191
癌症登记软体市场 - COVID-19 的增长、趋势、影响和预测 (2023-2028)Cancer Registry Software Market - Growth, Trends, and Forecasts (2023 - 2028) |
||||||
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
在 2022 年至 2027 年的预测期内，癌症登记软体市场的复合年增长率预计为 10.3%。
COVID-19 大流行导致大流行期间癌症诊断的显着下降以及化疗和手术等癌症支持治疗的减少。 此外，2020 年 6 月，欧洲胃肠内窥镜学会和欧洲胃肠内窥镜护士协会发布了指南。 在指导文件中，医生被建议在内镜切除后、手术切除后和息肉切除术后推迟癌症。 他们还建议由于感染风险而推迟对高危癌症患者的筛查，进一步减少治疗程序。
同样，2022 年 1 月发表的一项题为“COVID-19 大流行对基于人群的癌症登记的影响”的研究发现，全球许多癌症都处于 COVID-19 大流行的早期阶段。据报导，註册干扰了操作。 政府承诺支持未来的登记业务作为疾病控制的一项资产，以及向电子报告系统的过渡，将有助于确保全球癌症监测的可持续性。
预计未来的市场增长将受到癌症患病率上升、护理质量提高和医疗保健成本降低等因素的推动，再加上主要参与者的近期发展，例如产品/服务发布和兼併/收购。 根据全球癌症观察站（Globocan）2020年的统计数据，2020年全球将新增1930万癌症患者，而且这些患者的数量预计还会增加，到2040年将达到3020万。已经过去了。 此外，根据国际癌症研究机构 (IARC) 从 2021 年 7 月更新的估计，到 2040 年，全球将新增 2750 万癌症患者和 1630 万死亡病例，预计将增加。 如此高的负担在识别与癌症患病率和治疗相关的趋势方面提供了显着优势，增加了对癌症□□登记软体的需求。
同样，产品批准和发布也是市场增长的因素。 例如，2020 年 4 月，Elekta 的基于云的搜索和存储软体 ProKnow 获得了 CE 标誌。 借助供应商中立的 ProKnow，任何放射治疗部门都可以将大量数据安全地上传到 ProKnow 的云服务器，用于存储、分布轮廓、计划评估和同行评审以及关键指标分析（成果技术设施间合作等）。 ).
此外，2021 年 8 月，北爱尔兰癌症登记处 IARC 将提供新软体来促进癌症分期，从而更有效地收集可比数据以用于国家癌症管理。旨在改进 此外，2020 年 10 月，MOVEMBER 将推出世界上最大的前列腺癌患者登记网络，利用超过 130,000 名男性的“真实世界”经验来帮助治疗和护理这种疾病。有能力改变 这些努力通过改善基础设施和提供更高效和更具成本效益的数字解决方案来降低成本。 因此，由于上述因素，预计未来市场将增长。 然而，对患者数据隐私和安□□全的担忧预计会抑制市场增长。
主要市场趋势
预计在预测期内医院和诊所将占据重要的市场份额
医院部门是所研究市场增长的主要贡献者，因为大多数医院都拥有完善的基础设施。 癌症相关手术的增加增加了对医院的需求。 患者依赖医院作为他们的初级保健中心，预计在预测期内这种情况将持续下去。
在一些中欧和东欧 (CEE) 国家，医疗保健支出占 GDP 的比例落后于较富裕的欧盟 (EU) 国家。 包括波兰和捷克共和国在内的一些国家正感受到增加医疗保健投资的政治压力。 欧盟出版物 Sifted 于 2020 年 11 月报导称，欧洲有 626 家积极投资的数字健康公司，其中 63% 是在过去五年推出的。 此外，每个国家的手术数量也在推动市场的增长。 例如，The Innovative Partnership For Action Against Cancer 文章“解决放射肿瘤学和癌症手术的报销问题：挑战和选择”据报导是最常见的 丹麦每年进行 100 多例胰腺手术。 如此高的手术数量代表了患者对手术的采用率很高，预计随着时间的推移会出现增长。 手术数量的增加预计会增加患者对医院的偏好，因为医院的更高投资和资金使他们能够提供比其他设施更好的护理。
此外，医院癌症登记软体的可用性也是市场增长的因素之一。 例如，2021 年 9 月，印度医学研究委员会 (ICMR) 发布了一份题为“印度癌症临床病理学概况”的报告。 2021 年基于医院的癌症登记报告”，根据 NCRP，2012 年至 2019 年间，96 家医院登记了 13,32,207 例癌症病例。 其中，6,10,084 个被纳入分析。 因此，医院内癌症登记软体的可用性为患者提供了额外的好处。 由于这些优势，癌症登记软体市场有望在未来增长。
因此，由于上述因素，该细分市场在未来可能会增长。
北美有望在预测期内主导市场
预计北美地区将主导市场。 预计在预测期内，癌症等慢性病的流行和新产品的推出将推动该地区的市场。
根据《美国癌症协会杂誌》发表的《Cancer Statistics 2021》，美国估计有 190 万新诊断的癌症患者和 608,570 人死于癌症，这是市场预计将推动 此外，根据“Globocan 2020”，到 2020 年，该国的新癌症病例数将为 274,364 例，预计到 2040 年这一数字将上升到 400,564 例。 因此，该国癌症患者负担的增加预计将推动市场增长。
此外，癌症是墨西哥最常见的慢性疾病之一，根据 Globocan 2020 报告，2020 年约有 195,499 例新的癌症诊断，其中 90,222 例将因癌症死亡。 最常见的癌症是乳腺癌、前列腺癌、结直肠癌、甲状腺癌和宫颈癌。 此外，根据 Globocan 2020，墨西哥的癌症发病率预计到 2030 年将达到 254,665 人，到 2040 年将达到 323,432 人，并有望快速增长。 因此，该研究涵盖的市场预计将在本研究的预测期内增长。
同样，癌症登记处采用率的提高也有望促进市场增长。 根据美国疾病控制和预防中心的数据，截至 2022 年 1 月，超过 98% 的国家癌症登记计划 (NPCR) 资助的癌症登记处至少使用一种 Registry Plus 产品，其中一半您正在使用不止一种产品. Registry Plus 产品已成为许多癌症登记处的通用平台，符合 NPCR 电子数据交换标准，并有助于简化和自动化登记操作。 这样的采用率预计将推动未来的市场增长。
竞争格局
由于技术进步，大多数参与者都位于发展中国家。 然而，由于现代世界的互联便利，这些参与者也在向新兴国家扩张，并试图在这些国家建立市场。 市场部分分散，由几个主要参与者组成。 目前主导市场的公司包括 C/NET Solutions、Elekta、McKesson Corporation、IBM Corporation 和 Siemens Healthineers。
其他好处
- Excel 格式的市场预测 (ME) 表
- 三个月的分析师支持
内容
第1章介绍
- 研究假设和市场定义
- 调查范围
第2章研究方法论
第 3 章执行摘要
第4章市场动态
- 市场概览
- 市场驱动力
- 癌症患病率增加
- 提高医疗质量并降低医疗成本
- 市场製约因素
- 患者数据隐私和安□□全问题
- 波特的五力分析
- 新进入者的威胁
- 买方/消费者议价能力
- 供应商的议价能力
- 替代品的威胁
- 竞争公司之间的敌对关係
第 5 章市场细分（基于价值的市场规模：百万美元）
- 按部署模型
- 本地
- 云类型
- 按数据库类型
- 商业数据库
- 公共数据库
- 最终用户
- 政府/第三方组织
- 私人付款人
- 医院和诊所
- 其他
- 按地区
- 北美
- 美国
- 加拿大
- 墨西哥
- 欧洲
- 德国
- 英国
- 法国
- 意大利
- 西班牙
- 其他欧洲地区
- 亚太地区
- 中国
- 日本
- 印度
- 澳大利亚
- 韩国
- 其他亚太地区
- 中东和非洲
- 海湾合作委员会
- 南非
- 其他中东和非洲地区
- 南美洲地区
- 巴西
- 阿根廷
- 其他南美洲
- 北美
第6章竞争格局
- 公司简介
- C/NET Solutions
- Conduent, Inc
- Electronic Registry System, Inc.
- Elekta
- himagine solutions
- IBM Corporation
- McKesson Corporation
- NeuralFrame, Inc
- Onco, Inc.
- Ordinal Data, Inc
- Rocky Mountain Cancer Data Systems
- Siemens Healthineers
第7章 市场机会与今后动向
The cancer registry software market is projected to register a CAGR of 10.3% during the forecast period 2022-2027.
Due to the COVID-19 pandemic, the diagnostics for cancer decreased significantly during the pandemic, and there has been a decline in chemotherapy, surgery, and other supportive treatments for cancer. Further, in June 2020, guidance was issued by the European Society of Gastrointestinal Endoscopy and the European Society of Gastroenterology and Endoscopy Nurses and Associates. The guidance document advised that doctors postpone post-endoscopic resection, surgical resection of cancer, and post-polypectomy cancer. They also advised that screening of high-risk patients for cancer should also be postponed due to the risk of infection, which further led to the reduction in the treatment procedures.
Similarly, in January 2022, a research study published titled "Impact of the COVID-19 pandemic on population-based cancer registry" stated that many cancer registries worldwide reported disruption to their operations during the early COVID-19 pandemic. Governmental commitment to support future registry operations as an asset to disease control, alongside a move toward electronic reporting systems, will help to ensure the sustainability of cancer surveillance worldwide.
Factors such as increasing prevalence of cancer, and improving quality of care, and reducing healthcare costs coupled with recent developments by key players such as product/service launches and mergers & acquisitions are expected to increase the market growth in the upcoming future. According to the Global Cancer Observatory (Globocan) 2020 statistics, Globally, there were 19.3 million new cancer cases in 2020, these cases are expected to increase and reach up to 30.2 million in 2040. Additionally, according to estimates from the International Agency for Research on Cancer (IARC) updates from July 2021, by 2040, the global burden of cancers is expected to grow to 27.5 million new cancer cases and 16.3 million deaths worldwide. Such high burdens will increase the demand for cancer registry software as it would provide significant advantages to identifying the trend related to the prevalence and treatment of cancer.
Similarly, product approval and launches are other factors for the growth of the market. For instance, in April 2020, Elekta received a CE mark for its ProKnow cloud-based retrieval and storage software. With vendor-neutral ProKnow, any radiation therapy department can securely upload massive volumes of data to ProKnow's cloud server for storage, distributed contouring, plan evaluation and peer review, and analysis of key metrics - including outcomes technique evaluations and intra- and inter-institutional collaborations.
Additionally, in August 2021, IARC, The Northern Ireland Cancer Registry, and new software to facilitate cancer staging, aiming to improve national cancer control with a more effective collection of comparable data. Furthermore, in October 2020, MOVEMBER launched the world's largest network of prostate cancer patient registries, which will have the power to transform treatment and care of the disease by harnessing the 'real world' experiences of over 130,000 men. Such initiative improves the infrastructure and brings the cost down by providing a more efficient and cost-effective digital solution. Hence, due to the abovementioned factors, the market is expected to grow in the future. However, privacy and security concerns for patient data will be a restraint in the market growth.
Key Market Trends
Hospital & Medical Practice are Expected to Hold a Significant Market Share Over the Forecast Period
The hospital segment highly contributes to the growth of the studied market since the majority of the hospitals have a well-developed infrastructure. The rising cancer-related procedures are augmenting the demand of hospitals. Patients have been relying on hospitals as primary care centers, which is likely to continue during the forecast period.
In several Central and Eastern European (CEE) countries, healthcare spending as a percentage of GDP has lagged that of wealthier European Union (EU) nations. Some nations, notably Poland and the Czech Republic, now feel political pressure to increase healthcare investment. The EU publication Sifted reported in November 2020 that Europe had 626 actively funded digital health companies, with 63% of them launched in the prior five years. The high number of surgeries in different nations is also propelling the growth of the market. For Instance, The Innovative Partnership For Action Against Cancer article titled "Tackling reimbursement for radiation oncology and cancer surgery: challenges and options'' published in October 2020, reported that despite the small size of Denmark's population, the minimum number of cases is among the highest in Europe. In Denmark, more than 100 per year pancreatic surgeries are performed. Such a high number of surgeries depicts the high adoption of surgery among the patients and thus is expected to show growth over time. Hence, increasing surgeries would increase the patient preference for hospitals as it would provide them better care than other facilities due to high investments and funding available to the hospitals.
The availability of cancer registry software in hospitals is another factor in the growth of the market. For instance, in September 2021, the Indian Council of medical research (ICMR) published its report titled "Clinicopathological Profile of Cancers in India: A Report of Hospital-Based Cancer Registries, 2021," which stated that under the NCRP, 13,32,207 cancer cases were registered from 96 hospitals during 2012-19. Out of these, 6,10,084 cases were included for analysis. Thus, the availability of cancer registry software in the hospital provides additional advantages to the patients. Due to these advantages, the cancer registry software market is expected to grow in the upcoming future.
Hence, due to the above-mentioned factors, the market segment is likely to grow in the future.
North America is Expected to Dominate the Market Over the Forecast Period
The North American region is expected to dominate the market. The increasing prevalence of chronic disorders like cancer and new product launches are expected to drive the market in the region during the forecast period.
According to Cancer Statistics 2021, published in the American Cancer Society Journal, there are an estimated 1.9 million new cancer cases diagnosed and 608,570 cancer deaths in United States, which will drive the market significantly. moreover, according to Globocan 2020, the number of new cancer cases in the country was 274,364 in 2020, and this number is expected to increase to 400,564 by 2040. Thus, the growing burden of cancer cases in the country is expected to fuel the growth of the market.
Moreover, cancer is one of the most prevalent forms of chronic disease in Mexico, and as per the report of Globocan 2020, about 195,499 people were newly diagnosed with cancer in 2020, and 90,222 died because of it. The most prevalent forms of cancer were breast, prostate, colorectum, thyroid, and cervix uteri cancer. Furthermore, as per the Globocan 2020, the cancer incidence in Mexico is expected to reach 254,665 by 2030 and 323,432 by 2040, and thus, with the increasing burden of cancer cases in the country, the adoption of cancer registry software is expected to surge. Therefore, the studied market is expected to grow over the forecast period of the study.
Similarly, increasing the adoption of cancer registries would also increase the market growth. According to the Centers for Disease Control and Prevention, as of January 2022, over 98% of National Program of Cancer Registries (NPCR) funded cancer registries use at least one Registry Plus product, with more than half of those using two or more products. Registry Plus products have become a common platform among many cancer registries, helping them meet NPCR's standards for electronic data exchange, and streamlining and automating registry operations. Such an adoption rate would increase market growth in the upcoming future.
Competitive Landscape
Most of the players are based in developing counties due to more technological advancements. But due to the ease of connectivity in modern times, these players have also penetrated developing countries and are trying to establish a market in these countries as well. The market is partially fragmented and consists of several major players. Some of the companies which are currently dominating the market are C/NET Solutions, Elekta, McKesson Corporation, IBM Corporation, and Siemens Healthineers, among others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.2.1 Increasing Prevalence of Cancer
- 4.2.2 Improving Quality of Care and Reducing Healthcare Costs
- 4.3 Market Restraints
- 4.3.1 Privacy and Security Concerns for Patient Data
- 4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
- 5.1 By Deployment Model
- 5.1.1 On-Premise
- 5.1.2 Cloud-based
- 5.2 By Database Type
- 5.2.1 Commercial Database
- 5.2.2 Public Database
- 5.3 By End Use
- 5.3.1 Government & Third Party
- 5.3.2 Private Payers
- 5.3.3 Hospital & Medical Practice
- 5.3.4 Others
- 5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle-East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle-East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
- 5.4.1 North America
6 COMPETITIVE LANDSCAPE
- 6.1 Company Profiles
- 6.1.1 C/NET Solutions
- 6.1.2 Conduent, Inc
- 6.1.3 Electronic Registry System, Inc.
- 6.1.4 Elekta
- 6.1.5 himagine solutions
- 6.1.6 IBM Corporation
- 6.1.7 McKesson Corporation
- 6.1.8 NeuralFrame, Inc
- 6.1.9 Onco, Inc.
- 6.1.10 Ordinal Data, Inc
- 6.1.11 Rocky Mountain Cancer Data Systems
- 6.1.12 Siemens Healthineers
